Results from the phase III clinical trials for Bemiparin on diabetic foot ulcers
from Pipeline Review
Laboratorios Farmacéuticos Rovi S.A. announces that the analysis of the final results of the clinical trial of the efficacy and safety of Bemiparin in the treatment of diabetic foot ulcers does not show that Bemiparin is better treatment than a placebo. According to the Chief Executive Officer of ROVI, Juan López-Belmonte "the results do not confirm the positive data that we obtained in an earlier trial".
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063